BAFFR-targeting CAR-T cells for relapsed B-cell blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a type of B-cell blood cancer (like CLL/SLL, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, or large B-cell lymphoma) that has come back or not responded to treatment.
- You have failed or cannot tolerate at least two prior treatments (specific number depends on your cancer type).
- Your cancer cells have the BAFFR protein on their surface (this will be tested).
- You have measurable cancer on a scan.
- Your organs (heart, lungs, liver, kidneys) are working well enough, as checked by standard tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment that targets a protein called BAFFR on cancer cells. It is for people with B-cell lymphoma that has come back or not responded to previous treatments.
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
This trial tests a new type of CAR T-cell therapy that targets a protein called BAFF-R on your cancer cells. It is for people with B-cell ALL or lymphoma that has not responded to other treatments.
This trial tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack a protein called BAFF-R on your lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded well to at least two earlier treatments.
This Phase 1 study tests a new type of immune-cell therapy (CAR T cells) that targets BAFF-R to treat certain relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It aims to see if the treatment is safe and can shrink lymphoma in people who have tried prior therapies.
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.